JW (Cayman) Therapeutics Co. Ltd. (2126) AI Stock Analysis

• Market Cap: HK$2.51B
• Dividend Yield: N/A
• Average Volume (3M): 6.52M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: -10.78%
• EPS Growth: 24.88%
• Country: HK
• Employees: 281
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.70
• Shares Outstanding: 416,359,860
• 10 Day Avg. Volume: 5,278,596
• 30 Day Avg. Volume: 6,520,468
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$6.00
• Price Target Upside: 7.91% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: HK$6.00 ▲(7.91% Upside)

The overall stock score is primarily influenced by the company's strong technical momentum, which is offset by weak financial performance and valuation metrics. The stock's price is currently experiencing bullish momentum, but the lack of profitability and negative P/E ratio are significant concerns. The absence of earnings call data and corporate events means these factors did not impact the score.

JW (Cayman) Therapeutics Co. Ltd. Business Overview & Revenue Model

Company Description

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

JW (Cayman) Therapeutics Co. Ltd. generates revenue primarily through the commercialization of its CAR-T cell therapy products. These products are designed to treat various types of cancer by harnessing the patient's immune system to target and destroy cancer cells. The company earns money through the sale of these therapies to healthcare providers and institutions. Additionally, JW Therapeutics may engage in strategic partnerships and collaborations with other biotechnology firms, research institutions, and pharmaceutical companies to enhance its research capabilities and expand its market reach. These partnerships can also provide financial support, shared resources, and access to broader distribution networks, contributing to the company's revenue. Furthermore, JW Therapeutics may receive funding and grants from government bodies or non-profit organizations to support its research and development efforts, although this is typically a smaller portion of its revenue stream compared to product sales.

JW (Cayman) Therapeutics Co. Ltd. Financial Statement Overview

Summary

JW (Cayman) Therapeutics Co. Ltd. has demonstrated commendable revenue growth, yet continues to face challenges in achieving profitability. The balance sheet reflects financial stability with a strong cash reserve, but the ongoing net losses impact overall financial health. Cash flow from operations remains a concern, highlighting the need for the company to improve its operational efficiency and profitability to achieve sustainable growth.

Income Statement

The company has shown consistent revenue growth over the years, with a notable increase from 2020 onwards. However, profitability remains a significant issue as the company has reported negative net income and EBIT margins throughout the years, indicating ongoing operational challenges. The gross profit margin has improved slightly, yet the high net losses overshadow these gains.

Balance Sheet

The company's balance sheet is relatively stable with a strong cash position, as indicated by the significant cash and cash equivalents. The debt-to-equity ratio remains low, suggesting conservative leverage. However, the continued net losses have adversely affected the return on equity, which remains negative. The equity ratio indicates a solid equity base compared to total assets, pointing to financial stability despite ongoing losses.

Cash Flow

Operating cash flow has been consistently negative, reflecting challenges in generating cash from operations. The company has managed to maintain a positive cash position largely through financing activities. Free cash flow remains negative, indicating that the company is not yet self-sustaining and relies on external funding to cover operational and capital expenditures.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	158.22M	173.86M	145.70M	30.80M	0.00
Gross Profit	77.32M	88.22M	58.76M	9.04M	0.00
EBITDA	-381.58M	-655.75M	-752.27M	-738.70M	-454.04M
Net Income	-590.62M	-768.00M	-846.13M	-702.33M	-1.66B
Balance Sheet
Total Assets	1.68B	2.15B	2.79B	3.12B	3.78B
Cash, Cash Equivalents and Short-Term Investments	757.38M	1.01B	1.39B	1.84B	2.63B
Total Debt	422.40M	318.80M	279.13M	147.03M	123.59M
Total Liabilities	511.20M	462.26M	437.06M	325.75M	349.76M
Stockholders Equity	1.17B	1.68B	2.35B	2.79B	3.43B
Cash Flow
Free Cash Flow	-348.87M	-413.00M	-613.60M	-634.28M	-385.24M
Operating Cash Flow	-333.44M	-398.42M	-536.72M	-561.20M	-261.00M
Investing Cash Flow	-15.43M	9.90M	-124.08M	-137.13M	-91.91M
Financing Cash Flow	90.49M	275.00K	112.35M	-30.62M	2.86B

JW (Cayman) Therapeutics Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.56
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2126, the sentiment is Neutral. The current price of 5.56 is above the 20-day moving average (MA) of 5.41, above the 50-day MA of 4.19, and above the 200-day MA of 2.27, indicating a neutral trend. The MACD of 0.40 indicates Positive momentum. The RSI at 46.40 is Neutral, neither overbought nor oversold. The STOCH value of 33.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2126.

JW (Cayman) Therapeutics Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9966	61 Neutral	HK$9.98B	50.96	9.52%	―	185.36%	―
2157	57 Neutral	HK$17.49B	―	-21.42%	―	240.05%	-140.09%
2126	54 Neutral	HK$2.51B	―	-41.34%	―	-10.78%	24.88%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
2616	49 Neutral	HK$15.63B	―	-95.84%	―	-55.64%	-158.67%
2179	41 Neutral	HK$3.77B	―	-69.97%	―	―	3.30%
6955	―	HK$10.17B	101.75	4.95%	―	―	―

JW (Cayman) Therapeutics Co. Ltd. Corporate Events

JW Therapeutics to Review Interim Results in Upcoming Board Meeting

JW (Cayman) Therapeutics Co. Ltd. has announced a scheduled board meeting on August 27, 2025, to consider and approve the unaudited interim results for the first half of 2025. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and strategic direction for the upcoming months.

JW Therapeutics Announces Unanimous Approval of AGM Resolutions

JW (Cayman) Therapeutics Co. Ltd. held its Annual General Meeting on June 26, 2025, where all proposed ordinary resolutions were approved by poll. Key resolutions included the adoption of the company’s audited financial statements, re-election of directors, and re-appointment of Deloitte Touche Tohmatsu as auditor, reflecting strong shareholder support and stability in the company’s governance.

JW Therapeutics Approves License Agreement at EGM

JW (Cayman) Therapeutics Co. Ltd held an Extraordinary General Meeting (EGM) on June 3, 2025, where an ordinary resolution regarding the approval, ratification, and confirmation of a License Agreement was passed unanimously. The resolution’s approval, with 100% of the votes in favor, signifies a strategic move for the company, potentially enhancing its operational capabilities and market position in the biotechnology sector.

JW Therapeutics Advances Cancer Treatment with NMPA Acceptance

JW Therapeutics announced that the National Medical Products Administration of China has accepted the supplemental Biological License Application for Carteyva® as a second-line treatment for relapsed or refractory large B-cell lymphoma in patients ineligible for autologous stem cell transplantation. This development is supported by positive clinical results showing significant response rates and safety, addressing the urgent need for effective treatments for patients who cannot undergo standard therapies. The acceptance of this application could enhance JW Therapeutics’ position in the biotechnology industry and provide new hope for patients with limited treatment options.